Pfizer and Astellas' Padcev Antibody-Drug Conjugate under Review for Bladder Cancer Treatment in China
Thursday, 28 March 2024, 15:54
Pfizer and Astellas' Joint Venture
Astellas and Pfizer's antibody-drug conjugate, Padcev, has been accepted for review in China for first-line treatment of bladder cancer.
Key Highlights:
- Padcev under review in China for expanding treatment options
This development indicates the companies' commitment to advancing cancer therapies globally.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.